Role of diabetes and nitric oxide release duration on analytical performance of in vivo glucose biosensors

糖尿病和一氧化氮释放持续时间对体内葡萄糖生物传感器分析性能的作用

• 批准号: 9185309
• 负责人: Mark H Schoenfisch
• 金额: $ 47.64万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-12-01 至 2019-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9185309
• 关键词: Animals; Biological; Biosensor; Blood Glucose; Data; Development; Devices; Diabetes Mellitus; Disease; Evaluation; FDA approved; Family suidae; Foreign Bodies; Formulation; Funding; Future; Glucose; Goals; Histology; Impairment; Implant; In Vitro; Infection; Knowledge; Life; Membrane; Modeling; Needles; Nitric Oxide; Performance; Phase; Physiology; Polymers; Production; Reaction Time; Research; Risk; Rodent; Role; Running; Testing; Time; Tissues; Work; Wound Healing; base; biomaterial compatibility; design; diabetic; experimental study; glucose monitor; glucose sensor; implantation; improved; in vivo; monitoring device; non-diabetic; performance tests; public health relevance; response; sensor; usability

 DESCRIPTION: The objective of this project is to study the analytical performance benefits of nitric oxide (NO)-releasing percutaneously implanted glucose sensors in a diabetic swine model as a function of NO-release duration. Continuous glucose monitoring (CGM) devices with superior usability (i.e., for immediate use and extended duration) would greatly increase the ability of those afflicted with diabetes to successfully manage their disease. We have demonstrated in a non-diabetic (i.e., healthy) swine model that NO- releasing sensor membranes both lessen the FBR and facilitate improved analytical sensor performance up to 10 days-the longest duration evaluated. However, CGM devices are intended for diabetic use and longer implantation periods would improve device utility/value. The variance in FBR and in vivo sensor performance among healthy and diabetic subjects is currently unknown but likely large due to impaired physiology and lower endogenous NO production. We hypothesize that the improvements in FBR and sensor performance that we have observed via exogenous (i.e., polymeric) NO release in healthy animals will be even greater in diabetic subjects. Through our work, we will study the influence of extended NO release on tissue biocompatibility and sensor performance as a function of diabetes. In this respect, we will generate new knowledge on how diabetes influences the FBR and in vivo sensor performance.

 描述：该项目的目的是研究糖尿病猪模型中经皮植入的释放一氧化氮 (NO) 的葡萄糖传感器的分析性能优势，作为一氧化氮释放持续时间的函数。具有卓越可用性（即立即使用和延长持续时间）的连续血糖监测（CGM）设备将大大提高糖尿病患者成功控制疾病的能力。我们已经在非糖尿病（即健康）猪模型中证明，释放 NO 的传感器膜既可以减少 FBR，又可以提高分析传感器的性能，最长可达 10 天（评估的最长持续时间）。然而，CGM 设备适用于糖尿病患者，较长的植入周期将提高设备的实用性/价值。健康受试者和糖尿病受试者之间 FBR 和体内传感器性能的差异目前尚不清楚，但由于生理机能受损和内源性 NO 产生较低，可能差异很大。我们假设，我们通过健康动物中的外源（即聚合）NO 释放观察到的 FBR 和传感器性能的改善在糖尿病受试者中会更大。通过我们的工作，我们将研究延长的 NO 释放对组织生物相容性和传感器性能（作为糖尿病的函数）的影响。在这方面，我们将产生关于糖尿病如何影响 FBR 和体内传感器性能的新知识。